Last reviewed · How we verify
NCT06751901
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
Phase 2 trial testing Radiotherapy in Advanced NSCLC in 10 participants. Currently enrolling.
10 March 2026
Quick facts
| Lead sponsor | The First Affiliated Hospital of Nanchang University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 11 March 2024 |
| Primary completion | 10 March 2026 |
| Estimated completion | 10 June 2026 |
| Sites | 2 locations across China |
Drugs / interventions tested
- Radiotherapy — full drug profile →
- PD-1 inhibitor — full drug profile →
- Neoantigen-based peptide vaccine — full drug profile →
Conditions studied
- Advanced NSCLC — all drugs for Advanced NSCLC →
Sponsor
The First Affiliated Hospital of Nanchang University
Who can join
Adults 18 to 70, any sex, with Advanced NSCLC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, the investigators provide a combined treatment of personalized tumor neoantigen-based peptide vaccine, PD-1 Inhibitor, and radiotherapy to patients with advanced non-small cell lung cancer (NSCLC) progressed after second-line treatment. The investigators observe the objective response rate (ORR), disease control rate (DCR), adverse event (AE), serious adverse event (SAE), progression-free survival (PFS), and overall survival (OS) , aiming to evaluate the effectiveness and safety of the treatment.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Neoantigen-Based Immunotherapy in Lung Cancer: Advances, Challenges and Prospects.
Li X, Zhu YJ, Xue Y, Chen TT, et al · · 2025 · cited 6× · PMID 40563603 · DOI 10.3390/cancers17121953 -
Prospects and Challenges of Lung Cancer Vaccines.
Lin Z, Chen Z, Pei L, Chen Y, et al · · 2025 · cited 3× · PMID 40872921 · DOI 10.3390/vaccines13080836 -
Pipe dream to pipeline: Journey of cancer vaccines and the road ahead.
Onkar S, Bozkus CC, Saxena M, Bhardwaj N. · · 2026 · cited 1× · PMID 41576943 · DOI 10.1016/j.xcrm.2025.102575 -
Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future Directions.
Iranzo J, Giordano E, Marsicano RM, Trapani D, et al · · 2026 · PMID 41746058 · DOI 10.3390/vaccines14020135 -
Lung cancer vaccines to enhance immune checkpoint inhibitor therapy: evidence and future perspectives.
Tang Z, Zha L, Liang R, Li T. · · 2026 · PMID 41634728 · DOI 10.1186/s13045-026-01778-7 -
Directions of Immunotherapy for Non-Small-Cell Lung Cancer Treatment: Past, Present and Possible Future.
Leone GM, Scuderi G, Fagone P, Mangano K. · · 2025 · PMID 41303538 · DOI 10.3390/ijms262211055 -
Immune Surveillance and Immune Escape in Cancer: Mechanisms and Immunotherapy.
Peng Y, Zhan L, Shi J, Wang J, et al · · 2025 · PMID 41079643 · DOI 10.1002/mco2.70321
Verify or expand the search:
- PubMed search for NCT06751901
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Radiotherapy
Trials testing the same drug.
- NCT07497607 — Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma · Phase 2 · not yet recruiting
- NCT06813664 — ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI) · Phase 2 · not yet recruiting
- NCT07339774 — Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients · Phase 2 · recruiting
- NCT07353671 — Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis · Phase 2, PHASE3 · recruiting
- NCT07245745 — Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer · NA · recruiting
Other recruiting trials for Advanced NSCLC
Currently open trials in the same condition.
- NCT06924606 — Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy · Phase 2 · recruiting
- NCT06752044 — Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatm · NA · recruiting
- NCT06752057 — Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment · NA · recruiting
- NCT06751849 — Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment · Phase 2 · recruiting
- NCT06758557 — A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor · Phase 1, PHASE2 · recruiting
Other The First Affiliated Hospital of Nanchang University trials
Trials by the same sponsor.
- NCT06639516 — Therapeutic Effect of Bifidobacterium Longum in Patients with Acute Pancreatitis: a Randomized, Double-Blind, Placebo-Co · NA · not yet recruiting
- NCT07136961 — Efficacy and Safety of Robotic-assisted Bronchoscopy Combined With the ICNVA Strategy in Biopsy of Peripheral Pulmonary · NA · active not recruiting
- NCT06999031 — A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma · EARLY_PHASE1 · recruiting
- NCT06751966 — Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment · NA · recruiting
- NCT06752057 — Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06751901 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Nanchang University
- Last refreshed: 30 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06751901.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing